Since cyclamates were first introduced in the early 1950s, arguments have raged over the potential carcinogenicity of this artificial sweetener. Concern over the safety of cyclamates arises from observations that some individuals and experimental animals can metabolize cyclamate to cyclohexylamine and that cyclohexylamine has been shown to produce testicular atrophy in experimental animals. This study examines the absorption, excretion, and metabolism of cyclamate, particularly its conversion to cyclohexylamine. In addition, the potential toxicity and pharmacology of cyclohexylamine are discussed. Diabetes Care 12:50-55, 1989
T he artificial sweetener cyclamate, which is >30 times as sweet as sugar, was introduced as a food additive in 1951 (1, 2) . In many ways it appeared to be an ideal food additive, i.e., one that was only slowly and partially absorbed and once absorbed was rapidly excreted into the urine unchanged with minimal toxic action. However, two observations radically altered the world's view on the safety of cyclamate. The first was the observation by Kojima and Ichibagase (3) that some people and certain animals could metabolize cyclamate to cyclohexylamine. The second was a long-term study of rats involving the feeding of mixtures of cyclamate, saccharin, and cyclohexylamine, which caused an increased incidence of bladder tumors when compared with controls (4) . The latter observation led to the banning of cyclamates as a food additive in many From Allan J. Collings, PhD, Product Safety Consultant, 9 Arethusa Way, Bisley, Surrey, England CU2-49B2, UK.
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countries. Since then, arguments have raged over the carcinogenicity of cyclamate. Ultimately, at the request of the Food and Drug Administration (FDA), a National Academy of Sciences National Research Council Committee reviewed the evidence on the carcinogenicity of cyclamate, and in 1985 they issued their report (5) . The committee concluded that "the weight of experimental and epidemiological evidence does not indicate that cyclamate by itself is carcinogenic."
This conclusion was based on the results of several long-term studies on carcinogenicity, all of which proved negative, despite the occasional positive result in certain in vitro studies. In one study, N-nitrosomethyl urea was implanted into the bladder of rats with some given cyclamate and others water. Those receiving cyclamate showed a marked increase in the incidence of bladder tumors (33). The committee recommended that the study be repeated. They also recognized the problems associated with the metabolism of cyclamate to cyclohexylamine and saw the need to take the toxic action of this metabolite into consideration in the overall evaluation of cyclamate for widespread use (5) . In addition, the committee noted that there was suggestive evidence from in vivo and in vitro studies in animals that cyclamate had cancer-promoting or cocarcinogenic activity and, based on the epidemiological studies in humans, that the use of cyclamate-saccharin mixtures may be associated with a small increase in the risk of bladder cancer (5) .
To appreciate the significance of the conversion process, it is necessary to examine the absorption and excretion of both cyclamate and cyclohexylamine. Sodium cyclamate given by subcutaneous injection is rapidly excreted unchanged in the urine. In rats given a single oral dose of sodium cyclamate, the cyclamate rapidly appears in the urine and is followed by slow and steady
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excretion over the next 40 h. Once cyclamate has been absorbed into the body, it is rapidly excreted. The prolonged excretion pattern observed after oral administration suggests that absorption from the gastrointestinal tract is slow and protracted (6) . Cyclohexylamine given orally is rapidly absorbed and excreted.
MATERIALS AND METHODS
The conversion of cyclamate to cyclohexylamine has been observed in humans, rats, mice, and rabbits (2). However, not all humans or rats have the ability to convert. Studies have been undertaken in a number of species, including humans, to establish the nature of the conversion process. In one study, piglets with the ability to convert cyclamate to cyclohexylamine were maintained on a powdered diet containing 0.1 % sodium cyclamate (10) . After the ability to convert had been clearly established, the animals were placed on a cyclamatefree diet and given instead the same amount of cyclamate every day by subcutaneous injection as had been ingested through diet.
The pattern of urinary cyclamate excretion was typically erratic in the first part of the study, but when cyclamate was injected subcutaneously, there was a massive increase in the amount of cyclamate excreted in the urine. The change in the pattern of fecal cyclamate excretion was more dramatic. In the first part of the study, fecal excretion was erratic, but when cyclamate was given by injection rather than via the diet, the amount of cyclamate in the feces steadily decreased to zero. On return to cyclamate via diet, the fecal cyclamate levels gradually increased.
On examination of urinary cyclohexylamine excretion, the levels in the first part of the study were erratic, but once the route of administration was changed, the levels steadily decreased to zero. Once cyclamate was added to the diet, the levels of urinary and fecal cyclohexylamine gradually increased to the levels observed in the earlier part of the study. By combining
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NaCHS in diet- urinary and fecal cyclohexylamine excretion, the overall effect of changing the route of cyclamate administration from oral to subcutaneous could be seen ( Fig. 1 ).
Superimposing the graph of urinary cyclohexylamine excretion onto that of fecal cyclamate excretion showed that during the change from oral to subcutaneous administration and back, the level of urinary cyclohexylamine paralleled that of fecal cyclamate (Fig. 2) . From this it can be concluded that cyclamate must be present in the gastrointestinal tract for conversion to cyclohexylamine.
In the second study, piglets were fed a powdered diet containing 0.1 % sodium cyclamate throughout the study. Urine and feces were collected daily and analyzed for cyclamate and cyclohexylamine. The amount of cyclohexylamine excreted in the urine was erratic and varied widely from day to day. When oral antibiotics were given to the animals, the level of urinary and fecal cyclohexylamine rapidly decreased to almost zero (Fig. 3) . However, once antibiotic treatment had ceased, the ability to convert returned. At the end of the study, these animals were returned to a cyclamate-free diet until urine and feces were free of both cyclamate and cyclohexylamine. After a sample of the feces had been incubated with cyclamate, cyclohexylamine could be detected in the incubation mixture. Further evidence of conversion as a microbiological process can be seen in studies where nonconverter rats were turned into converters.
Laboratory rats that were not converters were fed cyclamate for 6 mo with no conversion being observed. When these animals were placed in the dirty cages vacated by converters, they acquired the ability to convert within days (10) . In humans and animals, cyclamate is not totally absorbed from the gastrointestinal tract, resulting in some cyclamate excretion in the feces.
In a study of four nonconverting human subjects, each subject was given the same amount of sodium cyclamate daily for 14 days (7). The amount was taken in divided doses between 0900 annd 2200. For the last two 3-day periods, urine and feces were collected for cyclamate analysis. The process was repeated three times, each with a different dose of cyclamate. Independent of the dosage, 40-70% of the cyclamate was excreted in the urine (Table 1) . With the slow and partial absorption characteristics of cyclamate, there is ample opportunity for metabolism to cyclohexylamine (7) .
When a converter was given a daily dose of cyclamate, cyclamate was present in the urine within 24 h. The urinary cyclamate levels followed an erratic course, sometimes high, sometimes low. However, when the ingestion of cyclamate ceased, the urinary levels decreased to zero over the next 3 days (8, 9) . In contrast, cyclohexylamine did not appear in the urine until 24 h after ingestion of cyclamate began. Cyclohexylamine continued to be excreted for 5 days after cyclamate ingestion had ceased.
The delay in the appearance of cyclohexylamine in the urine after ingestion of cyclamate was due to the amount of time taken for the cyclamate to reach the conversion site. It is unlikely the delay was caused by the induction of a metabolic process (Fig. 4) . This view is supported by the fact that the decay curve for cyclohexylamine after the withdrawal of cyclamate was the same shape as the buildup curve observed at the start of the study. This phenomenon may explain why the metabolism of cyclamate was not discovered in the earlier studies, in which only a single dose was given. Once conversion was found to occur, many studies were undertaken to estimate the incidence of human conversion. For these studies to be valid, it was necessary for the subjects to have been given repeated daily doses of cyclamate before having a 24-h urine sample taken for cyclohexylamine analysis (6,11-17; Table 1 ).
RESULTS
Over 80% of the subjects studied converted <0.15% of the ingested dose of cyclamate. Among the converters, conversion levels ranged from slightly >0.15% to a few people who showed conversion values of >60%. Both adults and children had been assessed for the ability to convert. In one study, 49 children between the ages of 3 and 18 yr were given 507 mg calcium cyclamate/day for 4 days (16). A 24-h urine sample was collected and analyzed for cyclohexylamine. Four of the children excreted cyclohexylamine that was of a conversion level up to 21.6%. How this could be considered "trace" conversion by the National Research Council is difficult to imagine (5) . In studies to determine the incidence of conversion, different dosage regimens have been used (Table 2 ). In a study that investigated this aspect of conversion, three converters were maintained on a fixed daily dose of cyclamate for 14 days, with total urine and feces collected over the last two 3-day periods. The study was repeated three times, each with a different daily dose of cyclamate. As the dose of cyclamate was increased, the proportion converted to cyclohexylamine decreased (7; Fig. 5 ). When assessing the significance of this conversion, the incidence and amount of conversion have to be taken into consideration. However, some of the approaches taken have limited validity. One study took the conversion levels of all the subjects and worked out the average conversion (31). The Food and Agriculture Organization and the World Health Organization used the degree of cyclamate absorption in a nonconverter as a reference and then considered a proportion (30%) of the unabsorbed cyclamate as available for conversion (32). In a nonconverter, 40-70% of ingested cyclamate was excreted in the urine. However, cyclamate was slowly and only partially absorbed. In high converters, the proportion of ingested cyclamate excreted in the urine was much lower than in nonconverters. This evidence strongly suggests that significant conversion occurs as the cyclamate passes over potential gastrointestinal absorption sites (7) .
If cyclamate is ever reintroduced, it must be at a reduced level; therefore, the amount of metabolism of low doses (higher conversion) has to be considered as the worst case. The worst case is represented by those who can convert >60% of ingested cyclamate. Although this represents only 0.5% of the population, it includes many people numerically.
Cyclohexylamine is an organic base with a pK a of 9.2. This means that at its physiological pH, it is almost totally ionized and exists as the cyclohexylamine ion. It is rapidly absorbed from the gastrointestinal tract and excreted largely unchanged into the urine. Studies have shown that further metabolism is possible (18, 19) , although no further metabolism has been detected in many studies (7, 18) .
In at least five 90-day feeding studies where cyclohexylamine (as the hydrogen chloride salt) was incorporated into the diet, testicular atrophy, reduced body weight gain, and hyperactivity were observed.
In feeding studies, rats were fed a powdered diet containing 0.01, 0.05, 0.2, 0.5, and 1% cyclohexylamine hydrochloride for 90 days. Body weight gain was reduced to the 0.2% dietary level in males and to 0.1% in females. The weight of the testes postmortem was reduced in the groups receiving 1.0 or 0.5% cyclohexylamine (equivalent to 434 and 175 mg cyclohexylamine • kg" 1 • day" 1 , respectively). Macroscopic examination of the testes showed that 13 of 15 males fed 1 % cyclohexylamine had small flabby testes with a bluishpurple tinge, typical of testicular atrophy.
Histologically, in the 1% group there was total bilateral degeneration of the testes (testicular atrophy) in 5 rats, 95% degeneration in 3 rats, ^70% degeneration in 4 rats, 40% degeneration in 1 rat, and < 1 % degeneration in the remaining 2 rats. This indicates that the effect of cyclohexylamine hydrochloride was severe in 13 out of 15 rats. Two of the rats in the 0.5% treatment group showed a marked increase in the number of tubules with evidence of early degeneration. The no-effect level for testicular atrophy was ~100 mg • kg" 1 • day" 1 (20) (21) (22) (23) (24) . 
METABOLISM OF CYCLAMATE DISCUSSION
W hen attempting to compare these results to humans, not knowing the mechanism that causes the testicular atrophy is frustrating. Efforts have been made to investigate this mechanism, but no satisfactory conclusion has been reached. Because converters have been found among children and adults, caution should be taken when considering the testicular toxicity of cyclohexylamine.
In the feeding studies, animals receiving cyclohexylamine did not gain weight as fast as the control animals (20, 23) . In pair-fed studies, in which the same amount of food consumed by the cyclohexylamine animals was fed to the controls, the control animals gained weight more rapidly than animals receiving cyclohexylamine hydrochloride (20, 23) .
In another study, animals receiving cyclohexylamine in their diet were more active than the control animals (20) . Whether this was due to the reduction of food intake or to the toxic action of cyclohexylamine is not known. The no-effect level for growth in the study was 50 mg • kg" 1 • day" 1 . Cyclohexylamine is pharmacologically active, with an action similar to reserpine (25) (26) (27) (28) (29) (30) . Administration of a single dose by the oral or intravenous routes causes a rise in blood pressure; in this instance, the mechanism of action is the release of norepinephrine from the tissues of the nervous system (30). It has been shown in humans that a peak cyclohexylamine blood level of 0.5-0.7 mg/L after the administration of a single oral dose of cyclohexylamine is sufficient to cause a significant rise in blood pressure. Cyclohexylamine blood levels of this nature have been found in human converters who ingest a regular amount of cyclamate, although no increase in blood pressure was observed (7) .
Whereas the acute pharmacological action of cyclohexylamine has been examined, the effects of chronic exposure have not. In one 90-day feeding study, blood pressure was measured immediately before termination. These animals did not show an increase in blood pressure; in fact, blood pressure was markedly reduced (20) .
Information from these studies precludes any assessment of the results of conversion of cyclamate to cyclohexylamine in people who have cardiovascular disease or who are receiving chemotherapy involving the cardiovascular or nervous system. The carcinogenicity of cyclamate is thus far from being resolved.
When studies on the mechanism and conversion of cyclamate are conducted, the following should be taken into account: /) the extent of conversion of cyclamate to cyclohexylamine-the worst case should be the point of reference, 2) the effect of cyclamate on developing and mature testes, 3) the effect of cyclohexylamine on growth, and 4) the acute and chronic pharmacological effects of cyclohexylamine and how it may affect various illnesses and patients receiving chemotherapy. To date, the debate has been dominated by the cancer-causing issue, which has been largely resolved, except for the problem of its possible cocarcinogenic activity. The problem surrounding the metabolism of cyclamate to cyclohexylamine still exists.
